pharma · Non-Hodgkin Lymphoma · Advanced Solid Tumors · ADCT
ADC Therapeutics
ADC Therapeutics SA
ADC Therapeutics is a pharma organization headquartered in Lausanne, CH. It trades on NYSE under ticker ADCT. Primary therapeutic focus areas include Non-Hodgkin Lymphoma, Advanced Solid Tumors, Relapsed or Refractory B-
Company details
- Status
- Public
- HQ
- Lausanne, Vaud, Switzerland, CH
- Founded
- 2011
- Employees
- 272
- Programs
- 30
- Drugs
- 15
- Patents
- 22
Quick answer
ADC Therapeutics is a pharma organization headquartered in Lausanne, CH. It trades on NYSE under ticker ADCT. Primary therapeutic focus areas include Non-Hodgkin Lymphoma, Advanced Solid Tumors, Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML). NovaPharmaNews links 30 clinical program(s), 1 drug profile(s), and 22 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (14), phase 2 (14), phase 3 (2).
Company snapshot
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. We are a pioneer in the ADC field with specialized capabilities unique to ADCs from clinical to manufacturing and commercialization with a proven track record that includes an approved and marketed prod
- 1 approved product(s) across US/EU regulatory metadata.
- 30 active pipeline program(s) linked via ClinicalTrials.gov.
- 22 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for ADC Therapeutics. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- trial_data
ADC Specialist Sinks on Safety Concerns: What Pharma Teams Need to Know
Recent coverage
Top assets
Lead pipeline drugs
- approved
- approved
- approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 2
- Phase 2
Momentum
Proprietary activity score for ADC Therapeutics.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for ADC Therapeutics.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is ADC Therapeutics?
-
Is ADC Therapeutics publicly traded?
-
What drugs does ADC Therapeutics develop or market?
-
What are the latest developments for ADC Therapeutics?
-
What therapeutic areas does ADC Therapeutics focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.